As a specialist in public health policy with a focus on fiscal accountability, I have spent decades analyzing how government budgets reflect a society’s true priorities. The current situation in Washington, D.C., serves as a cautionary tale of what happens when the desperate need for addiction services clashes with the cold reality of municipal budget deficits. D.C. is expected to receive over $100 million from a massive $50 billion national settlement, money intended to provide a lifeline to those ravaged by the opioid crisis. However, the city’s proposal to shift these funds to cover existing Medicaid obligations has sparked a fierce debate over ethics, legality, and the definition of progress. This interview explores the controversial practice of “supplanting” budgets, the tension between maintaining the status quo and funding innovation, and the deep-seated frustration of advocates who feel the city is failing to meet a lethal crisis with the “courageous” interventions it requires.
When a city decides to reallocate millions from its general budget to settlement funds for existing Medicaid obligations, what are the long-term consequences for the community’s public health infrastructure?
Using these settlement funds as a budget stopgap effectively freezes the progress we could be making against an escalating overdose crisis. In D.C., we are seeing at least $5.5 million being diverted to support treatment centers that were previously funded by the general budget, which means that instead of scaling up, the city is merely treading water. This prevents the rollout of new and innovative programs that are desperately needed to address a drug supply that is becoming increasingly unpredictable and lethal for our neighbors. It creates a stagnant environment where the multimillion-dollar cut of the settlement is spent on maintaining the status quo rather than saving additional lives. By keeping overall spending flat, the city misses a historic opportunity to expand its reach and truly remediate the damage caused by these pharmaceutical companies.
How does the legal distinction between “supplementing” and “supplanting” impact the actual delivery of services for those struggling with addiction?
The distinction is the difference between a lifeline and a revolving door, as the law specifically mandates that these funds must supplement, not replace, existing efforts. When the district uses $2.3 million of opioid settlement cash to cover its mandatory Medicaid contribution, it is a blatant budgeting tactic that violates the spirit of the litigation. For advocates on the ground, this feels like a “slap in the face” because it robs the community of the growth and innovation promised by the $100 million total settlement D.C. expects to receive over two decades. By substituting these dollars for general funding, the government is essentially paying off its own debts instead of expanding the reach of medication-assisted treatment. This legal “flouting” ensures that the budget remains legally certified but ethically hollow, leaving the infrastructure exactly where it was before the settlement arrived.
With over 80 individuals and 30 organizations protesting this budget move, what does their reaction reveal about the current state of trust between the government and the recovery community?
The outcry is a powerful indicator of a profound breach of trust, fueled by a sense of disappointment and even enragement among those who have lost loved ones to this crisis. When leaders like Chad Jackson, who is in recovery himself and chairs the advisory commission, call out this move as “supplantation,” it highlights a disconnect between bureaucratic convenience and the lived reality of residents. These stakeholders see a Department of Behavioral Health that is not meeting the mark for “courageous” interventions, even as the city manages to serve nearly 9,800 residents through existing providers. There is a sensory sharpness to this frustration; advocates feel the drug supply is moving faster than the city’s willingness to innovate. They know that without these settlement funds, the city would have been forced to find the money elsewhere to meet its obligations, making this feel like a shell game played with blood money.
How should city officials balance the immediate fiscal pressures of inflation and federal cuts with the specific mandate to use settlement funds for “new and innovative” remediation?
It is a delicate balance, but using settlement funds to fill budget holes caused by inflation is a short-sighted strategy that ignores the moral weight of why these funds exist. The $100 million D.C. is set to receive should be a catalyst for transformative change, not a way to keep spending flat for the 3,500 people currently receiving medication-assisted treatment for opioid addiction. True innovation requires the “nimbleness” to respond to a changing drug supply, but when funds are locked into existing Medicaid contributions, that flexibility completely vanishes. We must prioritize the specific reasons these funds were awarded, ensuring they foster new services rather than simply propping up a system that is already struggling to keep up with the crisis. If we don’t protect these funds from being used as a “rainy-day fund,” we are essentially telling the victims of the opioid crisis that their recovery is a secondary concern to balancing the books.
What is your forecast for the future of opioid settlement spending in urban centers like D.C.?
I forecast a significant increase in legal and political scrutiny as the full weight of these payouts begins to hit city accounts over the next several years. If D.C. continues to use these dollars for unauthorized purposes, the pressure from the Attorney General’s office and the Council’s Committee on Health will likely lead to stricter oversight or even litigation to freeze the disbursement of funds. Ultimately, the community’s demand for accountability will force a shift because the public refuses to watch more lives lost to bureaucratic convenience while $100 million sits in a fund being used to “pay off debts.” If the city does not begin to fund interventions that are more courageous and responsive to the unpredictable drug supply, the political cost for city leaders will become as high as the human cost we are currently seeing on our streets.
